Cytoreductive Surgery and Intraperitoneal Chemotherapy for Stomach CAncer: a Feasibility Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-01

Study Completion Date

2018-04-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rationale: For patients with peritoneal metastases of gastric origin, there is no consensus on the optimal treatment strategy. Several Asian and Western studies demonstrated hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CS) to result in a prolonged survival compared to palliative systemic treatment. Morbidity and mortality rates of HIPEC and CS appear to be acceptable. In the Netherlands, this treatment is not yet introduced, therefore patients with peritoneal metastases of gastric origin are precluded from surgery and will be treated with palliative chemotherapy or best support of care.

Objective: To assess the safety and feasibility of HIPEC and CS in Western patients with peritoneal metastases of gastric cancer, in terms of morbidity and mortality. Secondary objective is to determine the effect on survival and recurrence.

Study design: Mono centre prospective phase II single-arm feasibility study.

Study population: Western patients diagnosed with resectable (cT1-4b, N1-3) gastric cancer with clinical or pathologically proven peritoneal metastases without distant metastases.

Intervention: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery (CS) with Cisplatin.

Main study parameters/endpoints: Primary outcome is the safety and feasibility of the intervention, measured by the percentage of overall surgical complications grade ≥3 as stated by the Common Terminology Criteria for Adverse Events. Secondary outcomes are intraoperative events, postoperative morbidity and mortality, postoperative recovery, including quality of life, and disease free- and overall survival.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The additional burden for the patient mainly consists of HIPEC and CS.Furthermore, patients will undergo additional staging in order to exclude unresectable disease, and neoadjuvant chemotherapy regimen (3 drugs) instead of a palliative chemotherapy regimen (2 drugs). Postoperative care and outpatient visits are performed according to current protocols on HIPEC and CS for colon cancer and nation-wide protocols on gastric cancer surgery. The study is associated with a high risk classification. As there is a potential survival benefit, a small chance for curation and possibly a higher quality of life, we consider the additional burden and risks justified. This study is designed as a one group study, which eliminates group relatedness.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer

NCT01116791

Peritoneal Carcinomatosis Gastrointestinal Cancer

TERMINATED PHASE2

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Gastric Cancer

NCT03253939

Gastric Cancer Peritoneal Carcinomatosis

COMPLETED

Response Prediction of Hyperthermic Intraperitoneal Chemotherapy in Gastro- Intestinal Cancer

NCT05652348

Gastric Cancer Colon Cancer Peritoneal Carcinomatosis

RECRUITING

Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer

NCT04180761

Gastric Neoplasms

WITHDRAWN PHASE2

A Phase Ib/II Study of Efficacy and Feasibility of Cytoreductive Surgery, Extensive Peritoneal Lavage, Hyperthermicintraperitoneal Chemotherapy and Post-operative Intraperitoneal Chemotherapy Combination in Gastric Cancer With Peritoneal Metastasis

NCT02995850

Gastric Cancer With Peritoneal Metastasis (PCI<12)

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer Peritoneal Carcinomatosis HIPEC

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study population

Group Type EXPERIMENTAL

Perioperative chemotherapy

Intervention Type DRUG

Perioperative chemotherapy

Cytoreduction

Intervention Type PROCEDURE

Cytoreductive surgery

HIPEC

Intervention Type DRUG

Hyperthermic intraperitoneal chemotherapy (HIPEC) with 100mg/m2 cisplatin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Perioperative chemotherapy

Intervention Type DRUG

Cytoreduction

Cytoreductive surgery

Intervention Type PROCEDURE

HIPEC

Hyperthermic intraperitoneal chemotherapy (HIPEC) with 100mg/m2 cisplatin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically proven adenocarcinoma of the stomach.
* Surgical resectable carcinoma (T1-4b, N1-3) (table 1)
* Pathological proven peritoneal metastases
* Peritoneal Cancer Index (PCI) ≤12
* WHO performance status 0,1 or 2 and ASA 1-3
* Age ≥ 18
* Written informed consent

Exclusion Criteria

* Distant metastases other than peritoneal metastases
* Siewert type I/II gastro-esophageal junction tumor 22.
* Peritoneal carcinomatosis as a presentation of recurrent disease
* Pregnancy
* Any contraindication to cisplatin, e.g.

* Hypersensitivity
* HIV infection
* inadequate bone marrow function (ANC \<1.5x109/L or Platelets \<100x109/L)
* inadequate hepatic function (\>1.5 x ULN, ALAT and ASAT \>2.5 x ULN)
* inadequate renal function (Creatinine clearance \<50 ml/min)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No